Skip to main content

Advertisement

SpringerLink
Log in

Congenital Adrenal Hyperplasia: Issues in Diagnosis and Treatment in Children

  • Symposium on Pediatric Endocrinology
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Congenital adrenal hyperplasia (CAH) is a common disorder of impaired adrenal cortisol biosynthesis with associated androgen excess. The clinical presentation of 21-hydroxylase deficiency, the commonest cause of CAH, forms a spectrum and can be divided into classic and non-classic types. The former consists of life threatening salt wasting and non-life threatening simple virilizing phenotypes. Patients with the non-classic form are asymptomatic or have mild features of androgen excess. Most developed countries have newborn screening facilities for CAH. In the absence of newborn screening, the diagnosis of CAH may be missed or delayed. This can result in neonatal mortality in salt wasting forms and incorrect sex of rearing in females with simple virilizing form. The diagnosis is reached by demonstrating high serum 17-hydroxyprogesterone (17OHP) levels. Preterm birth and neonatal illness can cause physiological elevation of 17OHP, thus complicating the diagnosis of CAH in the newborn period. Prenatal diagnosis and treatment with dexamethasone to prevent virilization of affected female fetuses is another area of controversy. The management of CAH is complicated by the need to use supraphysiologic doses of glucocorticoids to suppress adrenal androgen synthesis. In this review, the authors address pertinent issues related to the diagnosis and management of CAH in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776–88.

    Article  CAS  PubMed  Google Scholar 

  2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21:245–91.

    CAS  PubMed  Google Scholar 

  3. Maiti A, Chatterjee S. Congenital adrenal hyperplasia: An Indian experience. J Paediatr Child Health. 2011;47:883–7.

    Article  PubMed  Google Scholar 

  4. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al; Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:4133–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Rama Devi AR, Naushad SM. Newborn screening in India. Indian J Pediatr. 2004;71:157–60.

    Article  PubMed  Google Scholar 

  6. Sharma S, Gupta DK. Male genitoplasty for 46 XX congenital adrenal hyperplasia patients presenting late and reared as males. Indian J Endocrinol Metab. 2012;16:935–8.

    Article  PubMed Central  PubMed  Google Scholar 

  7. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, et al. Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab. 1983;57:320–6.

    Article  CAS  PubMed  Google Scholar 

  8. Dauber A, Kellogg M, Majzoub JA. Monitoring of therapy in congenital adrenal hyperplasia. Clin Chem. 2010;56:1245–51.

    Article  CAS  PubMed  Google Scholar 

  9. Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, Schulze A, et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2004;89:3687–93.

    Article  CAS  PubMed  Google Scholar 

  10. Janzen N, Riepe FG, Peter M, Sander S, Steuerwald U, Korsch E, et al. Neonatal screening: Identification of children with 11β-hydroxylase deficiency by second-tier testing. Horm Res Paediatr. 2012;77:195–9.

    Article  CAS  PubMed  Google Scholar 

  11. Kösel S, Burggraf S, Fingerhut R, Dörr HG, Roscher AA, Olgemöller B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem. 2005;51:298–304.

    Article  PubMed  Google Scholar 

  12. Olgemöller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia: Adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003;88:5790–4.

    Article  PubMed  Google Scholar 

  13. Chennuri VS, Mithbawkar SM, Mokal RA, Desai MP. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J Pediatr. 2013;80:21–5.

    Article  PubMed  Google Scholar 

  14. van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004;151:U71–5.

    Article  PubMed  Google Scholar 

  15. Chan CL, McFann K, Taylor L, Wright D, Zeitler PS, Barker JM. Congenital adrenal hyperplasia and the second newborn screen. J Pediatr. 2013;163:109–13el.

    Article  CAS  PubMed  Google Scholar 

  16. Finkielstain GP, Chen W, Mehta SP, Fujimura FK, Hanna RM, Van Ryzin C, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2011;96:E161–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Mathur R, Menon PS, Kabra M, Goyal RK, Verma IC. Molecular characterization of mutations in Indian children with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Pediatr Endocrinol Metab. 2001;14:27–35.

    Article  CAS  PubMed  Google Scholar 

  18. Hirvikoski T, Lindholm T, Lajic S, Nordenström A. Gender role behaviour in prenatally Dexamethasone-treated children at risk for congenital adrenal hyperplasia—A pilot study. Acta Paediatr. 2011;100:e112–9.

    Article  PubMed  Google Scholar 

  19. Hirvikoski T, Nordenström A, Lindholm T, Lindblad F, Ritzén EM, Wedell A, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab. 2007;92:542–8.

    Article  CAS  PubMed  Google Scholar 

  20. Meyer-Bahlburg HF, Dolezal C, Haggerty R, Silverman M, New MI. Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:103–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Witchel SF, Miller WL. Prenatal treatment of congenital adrenal hyperplasia-not standard of care. J Genet Couns. 2012;21:615–24.

    Article  PubMed  Google Scholar 

  22. New MI, Abraham M, Yuen T, Lekarev O. An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia. Semin Reprod Med. 2012;30:396–9.

    Article  PubMed  Google Scholar 

  23. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002;87:4048–53.

    Article  Google Scholar 

  24. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth. Pediatrics. 2000;106:767–73.

    Article  CAS  PubMed  Google Scholar 

  25. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125–36.

    Article  PubMed  Google Scholar 

  26. Kulshreshtha B, Eunice M, Ammini AC. Pubertal development among girls with classical congenital adrenal hyperplasia initiated on treatment at different ages. Indian J Endocrinol Metab. 2012;16:599–603.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Muthusamy K, Elamin MB, Smushkin G, Murad MH, Lampropulos JF, Elamin KB, et al. Clinical review: Adult height in patients with congenital adrenal hyperplasia: A systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95:4161–72.

    Article  CAS  PubMed  Google Scholar 

  28. Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen W, et al. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child. 2002;87:139–44.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Muirhead S, Sellers EA, Guyda H, Canadian Pediatric Endocrine Group. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr. 2002;141:247–52.

    Article  CAS  PubMed  Google Scholar 

  30. Stikkelbroeck NM, Van’t Hof-Grootenboer BA, Hermus AR, Otten BJ, Van’t Hof MA. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: In early infancy and (pre)puberty. J Clin Endocrinol Metab. 2003;88:3525–30.

    Article  CAS  PubMed  Google Scholar 

  31. Bonfig W, Schmidt H, Schwarz HP. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr. 2011;75:32–7.

    Article  CAS  PubMed  Google Scholar 

  32. Charmandari E, Brook CG, Hindmarsh PC. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch Dis Child. 2002;86:266–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidence-based recommendation. J Clin Endocrinol Metab. 2009;94:3882–8.

    Article  CAS  PubMed  Google Scholar 

  34. Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Maronio F, Gennari M, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2003;88:5680–8.

    Article  CAS  PubMed  Google Scholar 

  35. Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: Deceleration of growth velocity during puberty. J Clin Endocrinol Metab. 2007;92:1635–9.

    Article  CAS  PubMed  Google Scholar 

  36. Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: A re-evaluation of relative potency. J Pediatr. 2003;143:402–5.

    Article  CAS  PubMed  Google Scholar 

  37. Bajpai A, Pandey RM, Kabra M, Menon PS. Growth pattern and final height in 21-hydroxylase deficiency. Indian Pediatr. 2007;44:771–3.

    PubMed  Google Scholar 

  38. Braga LH, Pippi Salle JL. Congenital adrenal hyperplasia: A critical appraisal of the evolution of feminizing genitoplasty and the controversies surrounding gender reassignment. Eur J Pediatr Surg. 2009;19:203–10.

    Article  CAS  PubMed  Google Scholar 

  39. Krege S, Walz KH, Hauffa BP, Körner I, Rübben H. Long-term follow-up of female patients with congenital adrenal hyperplasia from 21-hydroxylase deficiency, with special emphasis on the results of vaginoplasty. BJU Int. 2000;86:253–8.

    Article  CAS  PubMed  Google Scholar 

  40. Crouch NS, Liao LM, Woodhouse CR, Conway GS, Creighton SM. Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. J Urol. 2008;179:634–8.

    Article  PubMed  Google Scholar 

  41. Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2003;88:2993–8.

    Article  PubMed  Google Scholar 

  42. Deutschbein T, Unger N, Hauffa BP, Schaaf K, Mann K, Petersenn S. Monitoring medical treatment in adolescents and young adults with congenital adrenal hyperplasia: Utility of salivary 17α-hydroxyprogesterone day profiles. Exp Clin Endocrinol Diabetes. 2011;119:131–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sarafoglou K, Himes JH, Lacey JM, Netzel BC, Singh RJ, Matern D. Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia. Horm Res Paediatr. 2011;75:19–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Lin-Su K, Harbison MD, Lekarev O, Vogiatzi MG, New MI. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab. 2011;96:1710–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler Jr GB. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85:1114–20.

    Article  CAS  PubMed  Google Scholar 

  46. Verma S, Vanryzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2010;72:441–7.

    Article  CAS  Google Scholar 

  47. Bryan SM, Honour JW, Hindmarsh PC. Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab. 2009;94:3477–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

None.

Role of Funding Source

None.

Author information

Authors and Affiliations

  1. Pediatric Endocrine Division, Department of Pediatrics, Lady Hardinge Medical College and associated Kalawati Saran Children’s Hospital, New Delhi, 110001, India

    Rajni Sharma & Anju Seth

Authors
  1. Rajni Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anju Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anju Seth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, R., Seth, A. Congenital Adrenal Hyperplasia: Issues in Diagnosis and Treatment in Children. Indian J Pediatr 81, 178–185 (2014). https://doi.org/10.1007/s12098-013-1280-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-013-1280-8

Keywords

Search

Navigation